English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, March 17, 2023
乐普生物公布2022年度业绩
樂普生物公佈2022年度業績
Thursday, February 23, 2023
乐普生物和康诺亚共同宣布与阿斯利康就CMG901达成全球独家授权协议
樂普生物和康諾亞共同宣佈與阿斯利康就CMG901達成全球獨家授權協定
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
Thursday, September 29, 2022
乐普生物PD-1单抗普佑恒(TM)获批新适应症,MRG003获CDE纳入突破性治疗药物名单
樂普生物PD-1單抗普佑恒(TM)獲批新適應症,MRG003獲CDE納入突破性治療藥物名單
Lepu Biopharma: Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC
Thursday, August 25, 2022
乐普生物2022年上半年聚焦核心管线开发,加速商业化落地
樂普生物2022年上半年聚焦核心管線開發,加速商業化落地

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575